| ZFIN ID: ZDB-EXP-211026-18 |
Experiment Conditions Description: chemical treatment by injection: amyloid-beta, chemical treatment by environment: saracatinib
| chemical treatment by injection: amyloid-beta |
|---|
| Name: | chemical treatment by injection |
|---|---|
| Synonyms: | |
| Definition: | Chemical treatment in which the chemical is injected into the zebrafish. |
| Ontology: | Zebrafish Environment Condition Ontology [ZECO:0000237] |
| Name: | amyloid-beta |
|---|---|
| Synonyms: | amyloid beta, beta amyloid, beta-amyloid, beta-amyloids |
| Definition: | A peptide of 36-43 amino acids that is processed from the amyloid precursor protein. Appears to be the main constituent of amyloid plaques (deposits found in the brains of Alzheimer's disease patients). |
| Ontology: | ChEBI [CHEBI:64645] ( EBI ) |
| chemical treatment by environment: saracatinib |
|---|
| Name: | chemical treatment by environment |
|---|---|
| Synonyms: | |
| Definition: | Chemical treatment condition in which the chemical is introduced through the environment. For zebrafish this is the tank water. |
| Ontology: | Zebrafish Environment Condition Ontology [ZECO:0000238] |
| Name: | saracatinib |
|---|---|
| Synonyms: | AZ-10353926, AZD 0530, AZD-0530, AZD0530, N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-4-quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, N-(5-chloro-2H-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-[(oxan-4-yl)oxy]quinazolin-4-amine, saracatinib, saracatinibum |
| Definition: | A member of the class of quinazolines that is quinazoline substituted by (5-chloro-2H-1,3-benzodioxol-4-yl)amino, (oxan-4-yl)oxy and 2-(4-methylpiperazin-1-yl)ethoxy groups at positions 4, 5 and 7, respectively. It is a dual inhibitor of the tyrosine kinases c-Src and Abl (IC50 = 2.7 and 30 nM, respectively). Saracatinib was originally developed by AstraZeneca for the treatment of cancer but in 2019 it was granted orphan drug designation by the US Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis (IPF), a type of lung disease that results in scarring (fibrosis) of the lungs. |
| Ontology: | ChEBI [CHEBI:47458] ( EBI ) |
| Publication: | Özcan et al., 2020 |
|---|